Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $18.50 Consensus Target Price from Brokerages

Alphatec Holdings, Inc. (NASDAQ:ATEC) has earned an average rating of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $18.50.

ATEC has been the topic of a number of analyst reports. Wall Street Zen downgraded Alphatec from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Lake Street Capital raised Alphatec to a “buy” rating and set a $18.00 target price for the company in a research note on Monday, June 16th. Barclays reissued an “overweight” rating and set a $22.00 target price (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a research note on Friday, August 1st.

Insiders Place Their Bets

In other news, EVP David Sponsel sold 2,555 shares of Alphatec stock in a transaction on Friday, September 19th. The stock was sold at an average price of $15.34, for a total value of $39,193.70. Following the completion of the sale, the executive vice president directly owned 531,861 shares of the company’s stock, valued at approximately $8,158,747.74. The trade was a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Mortimer Berkowitz III sold 62,500 shares of Alphatec stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $15.97, for a total value of $998,125.00. Following the completion of the sale, the director directly owned 618,050 shares of the company’s stock, valued at $9,870,258.50. The trade was a 9.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 686,057 shares of company stock valued at $10,439,311. Insiders own 20.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ATEC. Nuveen LLC purchased a new stake in Alphatec during the 1st quarter worth about $135,874,000. American Century Companies Inc. lifted its holdings in Alphatec by 6.0% during the 2nd quarter. American Century Companies Inc. now owns 6,177,161 shares of the medical technology company’s stock worth $68,567,000 after buying an additional 347,130 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Alphatec by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company’s stock worth $60,990,000 after buying an additional 45,792 shares during the last quarter. Royal Bank of Canada lifted its holdings in Alphatec by 10.8% during the 1st quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company’s stock worth $35,773,000 after buying an additional 342,656 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Alphatec by 7.4% during the 2nd quarter. Geode Capital Management LLC now owns 2,697,541 shares of the medical technology company’s stock worth $29,946,000 after buying an additional 185,297 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Stock Performance

Shares of Alphatec stock opened at $13.76 on Tuesday. Alphatec has a one year low of $4.88 and a one year high of $16.70. The company has a market cap of $2.04 billion, a price-to-earnings ratio of -12.18 and a beta of 1.05. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88. The business’s 50 day moving average price is $14.98 and its 200 day moving average price is $12.49.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.08. The company had revenue of $185.54 million for the quarter, compared to analysts’ expectations of $178.85 million. During the same quarter in the previous year, the business posted ($0.29) EPS. The business’s quarterly revenue was up 27.5% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. On average, research analysts predict that Alphatec will post -1.08 EPS for the current year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.